Immatics Announces $125 Million Underwritten Offering
Summary
Houston, Texas and Tuebingen, Germany, December 05, 2025 Immatics N.V. (NASDAQ: IMTX, Immatics or the Company), a clinical-stage biopharmaceutical company and the global leader in precision targeting of PRAME, announced today that it has agreed to sell 12,500,000 ordinary shares at $10.00 per share in an underwritten offering. The offering is expected to close on December 8, 2025, subject to customary closing conditions.Jefferies, Leerink Partners and Cantor are acting as joint book-running managers for the offering.A registration statement relating to the securities has been filed with the U.S. Securities and Exchange Commission (the SEC) and was declared effective on April 3, 2025. Any offers, solicitations or offers to buy, or any sales of securities will be made in accordance with the registration requirements of the Securities Act of 1933, as amended.About ImmaticsImmatics is committed to making a meaningful impact on the lives of patients with cancer. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Immatics and its management, are inherently uncertain. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made.